DeCure for Diffuse large B-cell lymphoma of the central nervous system
DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for diffuse large B-cell lymphoma of the central nervous system — screening already-approved drugs against its 41-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleDiffuse large B-cell lymphoma of the central nervous system maps to a 41-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for diffuse large b-cell lymphoma of the central nervous system is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
ras homolog family member A (RHOA) — RHOA is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet gdpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5C4M · 1.3 Å · ligand GUANOSINE-5'-DIPHOSPHATE (GDP). Experimental structure, not a prediction.
What the evidence adds up to
Central nervous system relapse in diffuse large B-cell lymphoma is a rare but serious complication with poor outcomes. The reported prevalence of CNS relapse in DLBCL ranges from 1% to 30%, depending on risk factors and diagnostic methods. A 2024 comprehensive review states that understanding the epidemiology and clinical characteristics of CNS relapse is crucial for developing effective preventive and therapeutic strategies, but it does not provide any new trial data or specific survival or response numbers.
Primary central nervous system lymphoma is a rare extranodal non-Hodgkin's lymphoma, almost always diffuse large B-cell lymphoma. A 2025 review notes that studying this tumour is difficult because of its rarity and the consequent lack of statistically significant samples. That review analyses biological features, pathogenesis, tumour microenvironment, prognostic factors, and current treatment strategies, but it does not report any new clinical outcomes, response rates, or survival figures from a trial.
Both reviews are literature summaries, not reports of interventional studies. No drug, repurposed or otherwise, is mentioned in either abstract. No concrete numbers for survival, response rates, or sample sizes from a treatment study are provided. The abstracts do not describe any trial design, patient stratification, or funding source. What is still missing is any prospective trial testing a specific drug in this population, adequate sample sizes to generate statistically meaningful results, and the financial support needed to conduct such a study.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
International Journal of Medical Science and Clinical Research Studies · 2024 · 1 citations · open access
Prevalence of Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma: A Comprehensive Review
AbstractCentral nervous system (CNS) relapse in diffuse large B-cell lymphoma (DLBCL) is a rare but serious complication associated with poor outcomes. The prevalence of CNS relapse in DLBCL varies widely in the literature, ranging from 1% to 30%, depending on several risk factors and diagnostic methods. This article provides a comprehensive review of the current literature on the prevalence of CNS relapse in DLBCL, focusing on risk factors, diagnostic approaches, and treatment strategies. Understanding the epidemiology and clinical characteristics of CNS relapse in DLBCL is crucial for the development of effective preventive and therapeutic strategies.
Russian Journal of Archive of Pathology · 2025 · 0 citations
Primary lymphoma of the central nervous system
AbstractPrimary central nervous system lymphoma is a rare type of extranodal non-Hodgkin's lymphoma that occurs primarily in the central nervous system and represented by diffuse B-cell large cell lymphoma. Despite the fact that this tumor has been known for almost 100 years, studying it is difficult due to the rarity and, consequently, the limited number of statistically significant samples for research. This review analyzes the available literature data on the biological features of primary central nervous system lymphomas, pathogenesis and tumor microenvironment. In addition, we analyzed prognostic factors and current treatment strategies. The objective of this review is to determine the prospects for further study of this tumor.
Zenodo (CERN European Organization for Nuclear Research) · 2024 · 0 citations · open access
Prevalence of Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma: A Comprehensive Review
AbstractCentral nervous system (CNS) relapse in diffuse large B-cell lymphoma (DLBCL) is a rare but serious complication associated with poor outcomes. The prevalence of CNS relapse in DLBCL varies widely in the literature, ranging from 1% to 30%, depending on several risk factors and diagnostic methods. This article provides a comprehensive review of the current literature on the prevalence of CNS relapse in DLBCL, focusing on risk factors, diagnostic approaches, and treatment strategies. Understanding the epidemiology and clinical characteristics of CNS relapse in DLBCL is crucial for the development of effective preventive and therapeutic strategies.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
